More than 67,000 cases of deodorant sold at Walmart, Dollar Tree and on Amazon recalled
An enforcement report published by the agency showed A.P. Deauville launched a recall for over 67,000 cases of 'power fresh'-scented Power Stick for Her Roll-On Antiperspirant Deodorant, 'spring fresh'-scented Power Stick Invisible Protection Roll-On Antiperspirant Deodorant and Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant.
Advertisement
The company took that step July 10, according to the report.
The lot numbers of the recalled cases of Power Stick for Her Roll-On Antiperspirant Deodorant were 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341 and 082826E402, while the lot numbers for the affected Power Stick Invisible Protection Roll-On Antiperspirant included 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391 and 111626G231, the FDA enforcement report said.
4 Over 67,000 cases of Power Stick antiperspirant deodorant were recalled.
AP Deauville
4 The recall was issued on July 10, 2025, according to the FDA.
REUTERS
Advertisement
For the third variety, the lot numbers 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091 and 111626G221 were among those recalled.
The enforcement report identified 'cGMP deviations' as what prompted the recall, indicating it was related to the Current Good Manufacturing Practice regulations the FDA oversees.
A.P. Deauville says on its website it makes its antiperspirant deodorants at its 'FDA-regulated' factory in Pennsylvania.
4 The items were sold at Walmart, Dollar Tree and on Amazon.
jetcityimage – stock.adobe.com
Advertisement
4 An undisclosed manufacturing problem prompted the recall.
Christopher Sadowski
The cases of the recalled Power Stick deodorant were shipped nationwide, according to the FDA enforcement report.
The deodorant is sold at Walmart, Dollar Tree and Amazon.
Advertisement
A.P. Deauville is based in Easton, a city in eastern Pennsylvania that sits near the state's border with neighboring New Jersey.
In addition to deodorant, the company makes shampoos, conditioners, lotion, body washes and facial wipes, according to its website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 minutes ago
- Business Wire
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor. Ateganosine is a first-in-class small molecule that compromises telomere structure and function in cancer cells, leading to rapid tumor cell elimination and specific immune memory. Through telomerase-mediated action, ateganosine reverses intrinsic or acquired resistance to immune checkpoint inhibitors (ICIs). 'FDA's Fast Track Designation recognizes ateganosine's potential as a new therapeutic paradigm in cancer treatment science. Ateganosine is the first and only anticancer treatment of its kind that we are aware of in clinical development,' stated MAIA Chairman and CEO Vlad Vitoc, M.D. 'If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year. If approved, ateganosine would have a first-to-market competitive position within a $34 billion NSCLC treatment market with significant unmet medical need.' NSCLC represents one of the largest global oncology indications. The market was valued at $34.1B in 2024 and is projected to reach $68.8B by 2033 with a projected CAGR of 8.1%. 1 'This is an important milestone for MAIA's clinical development program. Ateganosine has demonstrated robust preclinical efficacy and superior clinical median overall survival compared to other FDA-approved treatments for NSCLC patients with prior disease progression on platinum-based chemotherapy and anti-PD-(L)1 antibody. Additionally, advanced NSCLC is a devastating disease that clearly meets the criteria for a serious condition with unmet medical need. Both are key criteria for the Fast Track designation,' said K. Robinson Lewis, Vice President, Head of Regulatory and Quality at MAIA. 'We intend to utilize the incentives of the Fast Track Program to expedite the development and review of ateganosine and bring patient access sooner.' The FDA Fast Track is a process designed to facilitate development and expedite the review of drugs for treating serious conditions and filling an unmet medical need, as in providing a therapy where none exists or which may be potentially better than available therapy. If relevant criteria are met during the Fast Track process, a drug will be eligible for FDA Accelerated Approval and Priority Review (FDA decision within six months). MAIA's most recent data from the pivotal Phase 2 THIO-101 clinical trial of ateganosine as of May 15, 2025 showed median overall survival (OS) of 17.8 months in a heavily pre-treated population. As of the data cut-off date, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care chemotherapy treatments for NSCLC in a similar setting have shown overall survival of 5 to 6 months. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About THIO-101 Phase 2 Clinical Trial THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine's anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
CNET
8 minutes ago
- CNET
Think Higher SPF Is Better? Experts Say 30–50 Is Where It's At
Staying hydrated and cool might be at the top of your list this summer, but don't forget about sunscreen. Protecting your skin from the sun's UV rays is essential—not just to prevent sunburn, but to lower your risk of skin cancer and early signs of aging. With so many SPF options lining store shelves, it's easy to feel overwhelmed. That's why we asked a dermatologist to break down exactly what SPF number you should be reaching for. What is SPF? SPF, or sun protection factor, describes the amount of solar energy needed to produce a sunburn on protected skin relative to unprotected skin, according to the US Food and Drug Administration. Logic would follow, then, that wearing a higher SPF would offer you better protection when you're out and about, basking in the sun's rays. Is a higher SPF better? Is higher SPF sunscreen more protective in a measurable way that actually matters? The tested difference between SPF 30 and SPF 50 is small, according to Dr. Steven Daveluy, board-certified dermatologist and program director at Wayne State University Department of Dermatology. There was a difference of 96.7% blocking versus 98% blocking, in one example he provided. Research on people wearing sunscreen out in "real life" has suggested higher SPFs are more protective, Daveluy said in an email. Combine this with the fact you're probably not wearing enough sunscreen -- studies have shown people apply only 25% to 50% of the amount that they should, Daveluy said -- and a higher SPF may come out reasonably more protective. "You should use about 1 ounce of sunscreen to cover your head, neck, arms and legs when wearing shorts and a T-shirt," Daveluy recommended, adding that people without hair should use a little more. "That means your 3-ounce tube of sunscreen is only three applications," Daveluy said. "Most people are not using that amount." What is the minimum SPF you need in a sunscreen? The American Academy of Dermatology Association recommends your sunscreen be SPF 30 or higher. It also recommends you look for sunscreen that has broad-spectrum protection (it protects against UVA and UVB rays) and make sure it's water-resistant. "If you follow the recommendations for the proper amount of sunscreen, then SPF 30 is great," Daveluy said. If you think you're skimping on the layers, though, a higher SPF could offer more benefit. He added that he generally recommends looking for at least SPF 50 or 60. Does skin tone matter when choosing an SPF? People with darker skin tones have more melanin, which does offer some protection from the sun's damaging rays. For this reason, skin cancer rates in people of color are lower than rates in white people, but the risk isn't zero. Research also suggests that people of color may be more likely to experience a missed or late diagnosis of skin cancer, making outcomes more dangerous. (It's also important to note that melanoma can have other causes besides exposure to sunlight or UV rays, and can show up in areas not typically exposed to sun.) "SPF 30 is the minimum for everyone," Daveluy said. He added that tinted sunscreens may be a better fit for darker skin tones, leaving less of a white cast. "If you have very fair skin, the higher [SPF] numbers may be a good idea, especially if you aren't using the proper amount, because you will see the consequences of underuse more easily," Daveluy said. Sunscreen red flags As long as you're wearing a minimum of SPF 30, applying it properly and also looking for products that are broad spectrum and water resistant, you've got the basics down. Daveluy added that for people with sensitive skin, finding a mineral sunscreen with "active ingredients of zinc and/or titanium" may be a good choice. Daveluy pointed out other measures of protecting yourself from the sun, including wearing a wide-brimmed hat, sun-protective clothing and hanging out in the shade when possible. But don't forget that sunscreen has a proven safety record going back for decades, he said. "The biggest red flags for sunscreen are any people or reports that try to tell you sunscreen isn't safe," Daveluy said.
Time Business News
16 minutes ago
- Time Business News
Pregabalin 150mg for Post-Herpetic Neuralgia: Fast Relief?
Post-herpetic neuralgia (PHN) is one of the most common and challenging complications of shingles, affecting the nerves and causing persistent pain that can last for months or even years. Patients with PHN often struggle to find effective and sustainable relief. One medication that has gained attention in this domain is Pregabalin 150mg, known for its nerve-calming properties and effectiveness in chronic neuropathic pain. But how fast does it work? And is it truly a reliable solution? In this article, we explore the role of Pregabalin 150mg in managing post-herpetic neuralgia, its mechanism of action, how quickly it provides relief, and what patients can realistically expect. Understanding Post-Herpetic Neuralgia Post-herpetic neuralgia is nerve pain that persists after a shingles infection (herpes zoster) has healed. It typically affects older adults and results from nerve damage caused by the varicella-zoster virus. Symptoms include: Burning, stabbing, or aching pain in the area where shingles occurred Heightened skin sensitivity Pain lasting more than three months after the rash clears Sleep disturbances and emotional distress The intensity and duration of PHN pain can vary greatly between individuals, making personalized treatment crucial. What is Pregabalin 150mg? Pregabalin 150mg, sold under brand names like Lyrica, is an anticonvulsant and anxiolytic medication that is FDA-approved for treating neuropathic pain, including post-herpetic neuralgia. It belongs to a class of drugs known as gabapentinoids, which modulate nerve activity. The 150mg dose is considered a mid-range starting or maintenance dose in PHN treatment and can be adjusted based on response and tolerance. How Does Pregabalin Work for PHN? Pregabalin doesn't work by blocking pain signals directly like opioids or NSAIDs. Instead, it binds to the alpha-2-delta subunit of voltage-gated calcium channels in overexcited nerves. This reduces the release of neurotransmitters such as glutamate, norepinephrine, and substance P, all of which are associated with pain transmission and nerve sensitization. This calms the overactive nerves, reducing the abnormal firing that contributes to the burning and tingling sensations in PHN. How Fast Does Pregabalin 150mg Work for PHN? This is the key question for most patients suffering from PHN. The onset of relief depends on several factors, including the individual's pain intensity, how long they've had PHN, and their sensitivity to medications. Timeline of Effects: Initial Response : Some patients begin noticing relief within 3 to 5 days , especially improved sleep due to reduced nighttime pain. : Some patients begin noticing relief , especially improved sleep due to reduced nighttime pain. Peak Relief : Most patients experience significant improvement within 2 to 4 weeks at the 150mg dose. : Most patients experience at the 150mg dose. Full Effectiveness: It may take up to 6 to 8 weeks for the full benefits, especially in long-standing or severe PHN cases. If relief is insufficient, the dose may be increased to 300mg per day under medical supervision. Clinical Evidence Supporting Pregabalin for PHN Multiple clinical studies have confirmed Pregabalin's effectiveness in reducing PHN pain: A randomized controlled trial published in Neurology found that patients on Pregabalin 150–600mg/day had significantly lower pain scores and better sleep quality compared to placebo. found that had significantly lower pain scores and better sleep quality compared to placebo. In another meta-analysis of over 1000 patients, Pregabalin showed substantial relief within 2 weeks, particularly in patients with moderate to severe pain. These findings reinforce its role as a first-line treatment in neuropathic pain management. Advantages of Pregabalin 150mg for PHN ✅ Targeted Nerve Pain Relief Pregabalin targets nerve-related pain specifically, which is crucial for conditions like PHN where traditional painkillers may not work. ✅ Improved Sleep Quality PHN pain often flares up at night. Pregabalin helps improve sleep by calming nerve activity and reducing nighttime pain. ✅ Better Quality of Life Reduction in pain leads to better mood, fewer depressive symptoms, and improved physical activity levels. ✅ Fewer Gastrointestinal Side Effects Compared to NSAIDs and opioids, Pregabalin does not cause stomach ulcers or constipation. Potential Side Effects of Pregabalin 150mg While effective, Pregabalin is not without side effects, particularly in elderly patients. Common side effects include: Dizziness or drowsiness Blurred vision Weight gain Dry mouth Swelling in hands or feet Serious but rare effects: Suicidal thoughts Severe allergic reactions Mood changes Starting with a low dose and gradually increasing to 150mg can minimize side effects. Who Should Not Take Pregabalin? Not everyone is an ideal candidate for Pregabalin. Caution is advised in: Elderly patients with balance issues (due to risk of falls) with balance issues (due to risk of falls) Patients with kidney disease (Pregabalin is renally excreted) (Pregabalin is renally excreted) People with a history of substance misuse Those who drive or operate machinery until they know how it affects them Always consult a healthcare provider before starting Pregabalin. Pregabalin 150mg: Dosage & Administration for PHN Starting Dose : Often 75mg twice daily or 150mg once at night : Often 75mg twice daily or 150mg once at night Maintenance : 150–300mg/day in divided doses : 150–300mg/day in divided doses Maximum Dose: 600mg/day (usually reserved for severe or unresponsive cases) Food doesn't affect its absorption, so it can be taken with or without meals. Patient Tips for Best Results Take consistently at the same time daily at the same time daily Do not stop suddenly – taper down gradually to avoid withdrawal – taper down gradually to avoid withdrawal Track pain levels – use a journal to monitor response – use a journal to monitor response Report side effects – dizziness and swelling should be noted – dizziness and swelling should be noted Combine with lifestyle support – gentle exercise, meditation, and physical therapy can boost recovery What to Expect After Starting Pregabalin 150mg Week Expected Outcome Week 1 Mild pain reduction, better sleep, possible dizziness Week 2 Noticeable drop in burning/stabbing sensations Maximum effect, pain is significantly more manageable Steady relief, improved daytime function Week 6+ Maximum effect, pain significantly more manageable Note: If no benefit is seen by Week 4, dosage adjustment or medication change may be necessary. Is Pregabalin 150mg a Long-Term Solution? For many patients, yes. Some continue taking it for months or even years under medical supervision if PHN is persistent. Others taper off as the nerve heals. However, long-term use requires regular monitoring, especially in elderly patients, to prevent dependence or tolerance. Conclusion: Is Pregabalin 150mg the Answer for PHN? When used under proper medical guidance and combined with supportive therapies, Pregabalin 150mg can significantly improve the lives of those suffering from PHN. It might not cure the condition, but for many, it restores comfort, mobility, and peace of mind. FAQs Q: Is Pregabalin 150mg addictive? A: While not highly addictive, it can cause dependence if misused or taken long-term without supervision. Q: Can I take Pregabalin with other medications for PHN? A: Yes, but always check for interactions. Tricyclic antidepressants and topical lidocaine are sometimes used together with Pregabalin. Q: Can Pregabalin cure PHN? A: No, it manages symptoms. The goal is to reduce pain while the nerve heals naturally over time. Q: What if 150mg doesn't work? A: Your doctor may increase the dose or combine it with another therapy. TIME BUSINESS NEWS
